• JIC Venture Growth Investments took a minority equity stake in SiccaNova Therapeutics via its JIC Venture Growth Fund 2.
• Capital injection targets clinical development of SiccaNova’s lead xerostomia drug candidate XF8302.
• XF8302 completed Phase 1 trials in Japan, Europe; Phase 2 preparation underway in Japan for Sjögren's syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JIC Venture Growth Investments Co Ltd published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.